Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) Research

Shenzhen Hepalink Pharmaceutical Group Co., Ltd., established in 1998 and headquartered in Shenzhen, People's Republic of China, operates as a global pharmaceutical enterprise. Having adopted its current name in February 2017 (formerly Shenzhen Hepalink Pharmaceutical Co.,Ltd.), the company specializes in the production and worldwide distribution of pharmaceutical products across diverse markets including Hong Kong, the United States, Europe, and mainland China. Its comprehensive business operations are structured into four key divisions: finished dose pharmaceutical products, active pharmaceutical ingredients (APIs), contract development and manufacturing organization (CDMO) services, and an 'other' category. Hepalink's product lineup prominently features finished dosage forms such as enoxaparin sodium injection, alongside essential APIs like heparin sodium and enoxaparin sodium, and other specialized APIs including pancreatin. Beyond manufacturing, the firm provides extensive services covering research and development, production, quality control, and program management. It also engages in the innovation and creation of sophisticated biopharmaceuticals, specifically recombinant products, crucial non-viral vectors, gene therapy intermediates, and pharmaceutical compounds originating from natural sources. Further diversifying its portfolio, Hepalink's broader interests span property management, investment and biopharmaceutical technology consulting, and equity and venture investments. The company also undertakes general biopharmaceutical research, development, and production, manages the sale of heparin sodium, offers various pharmaceutical-related services, and actively trades medical and biopharmaceutical goods.

Open Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.